NCT04282187 2026-03-16
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
University of Washington
Phase 2 Recruiting
Clinical Trials
8 trialsNCT07464951 2026-03-11
CART123
Children's Hospital of Philadelphia
Phase 1 Not yet recruiting
NCT03681561 2026-03-09
Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma
Big Ten Cancer Research Consortium
Phase 1/2 Recruiting
NCT07454226 2026-03-06
ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL
Institute of Hematology & Blood Diseases Hospital, China
Phase NA Not yet recruiting
NCT02974647 2026-02-27
Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07025538 2026-02-23
Biomarker-Guided Ruxolitinib for the Prevention of Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation
City of Hope Medical Center
Phase 1 Suspended
NCT03514069 2026-02-19
Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma
Case Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT07228624 2026-02-19
Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes
Fred Hutchinson Cancer Center
Phase 2 Recruiting